ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 123 • 2014 ACR/ARHP Annual Meeting

    Combination with Joint Power Doppler Signals with Anti-Citrullinated Peptide Antibody Predicts Joint Destruction in Rheumatoid Arthritis

    Yohei Kirino1, Maasa Hama1, Kaoru Minegishi-Takase1, Yosuke Kunishita1, Daiga Kishimoto1, Ryusuke Yoshimi1, Yukiko Asami1, Atsushi Ihata2, Shigeru Ohno3, Atsuhisa Ueda1, Mitsuhiro Takeno4 and Ishigatsubo Yoshiaki1, 1Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, 3Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, 4Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan

    Background/Purpose ,  Categorizing RA patients who require intensive treatments is highly warranted to optimize the therapy and to avoid overtreatments.  We here evaluated the use…
  • Abstract Number: 2817 • 2014 ACR/ARHP Annual Meeting

    Histone Deacetylase One Contributes to the Auto-Aggressive Phenotype of Rheumatoid Arthritis

    Sarah Hawtree1, Munitta Muthana1, J. Mark Wilkinson2, Anthony G. Wilson1 and Mohammed Akil3, 1Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, 2Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, United Kingdom, 3Rheumatology Department, Sheffield South Yorkshire, United Kingdom

    Background/Purpose Rheumatoid arthritis (RA) is a chronic, autoimmune, inflammatory disease that affects synovial joints. A key characteristic of RA is hyperplasia of fibroblast-like synoviocytes (FLS)…
  • Abstract Number: 1845 • 2014 ACR/ARHP Annual Meeting

    Tocilizumab Combination Therapy or Monotherapy or Methotrexate Monotherapy in Methotrexate-Naive Patients with Early Rheumatoid Arthritis: 2-Year Clinical and Radiographic Results from a Randomized, Placebo-Controlled Trial

    Gerd Burmester1, William Rigby2, Ronald F. van Vollenhoven3, Jonathan Kay4, Andrea Rubbert-Roth5, Ricardo Blanco6, Ariella Kelman7, Sophie Dimonaco8 and Nina Mitchell8, 1Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, 2Geisel School of Medicine at Dartmouth, Lebanon, NH, 3Karolinska Institute, Stockholm, Sweden, 4UMass Memorial Medical Center, Worcester, MA, 5University of Cologne, Cologne, Germany, 6Hospital Marques de Valdecilla, Santander, Spain, 7Genentech, South San Francisco, CA, 8Roche Products Ltd., Welwyn Garden City, United Kingdom

    Background/Purpose: Treatment with tocilizumab (TCZ) in combination with MTX or as monotherapy (Mono) in MTX-naive patients (pts) with early RA resulted in improved signs and…
  • Abstract Number: 508 • 2014 ACR/ARHP Annual Meeting

    Relationship Between NK Cell Count and Important Safety Events in Rheumatoid Arthritis Patients Treated with Tofacitinib

    R. van Vollenhoven1, Y. Tanaka2, R. Riese3, M. Lamba3, T. Kawabata3, T. Hirose4, S. Toyoizumi4, A. Hazra3 and S. Krishnaswami3, 1The Karolinska Institute, Stockholm, Sweden, 2University of Occupational and Environmental Health, Kitakyushu, Japan, 3Pfizer Inc, Groton, CT, 4Pfizer Inc, Tokyo, Japan

    Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Cytokines (e.g. interleukin [IL]-2, -4, -7, -15, -21) involved…
  • Abstract Number: 2785 • 2014 ACR/ARHP Annual Meeting

    Joint Specific Positional Differences in Coding and Noncoding Transcriptome of Synovial Fibroblasts As a Determinant of the Susceptibility of Synovial Joints to Rheumatoid Arthritis

    Caroline Ospelt1, Maria Armaka2, Giancarlo Russo3, Anna Bratus3, Michelle Trenkmann4, Emmanuel Karouzakis1, Christoph Kolling5, Renate E. Gay4, George Kollias6, Steffen Gay1 and Mojca Frank Bertoncelj1, 1Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2Institute of Immunology,, Biomedical Sciences Research Center 'Alexander Fleming', Vari, Greece, 3Functional Genomics Center Zurich, ETH Zurich and University of Zurich, Zurich, Switzerland, 4Center of Experimental Rheumatology, Zurich University Hospital, Zurich, Switzerland, 5Schulthess Clinic, Zurich, Switzerland, 6Institute of Immunology, Biomedical Sciences Research Center 'Alexander Fleming', Vari, Greece

    Background/Purpose The molecular mechanisms underlying the topographic differences in the susceptibility of synovial joints to develop rheumatoid arthritis (RA) are unknown. Positional embryonic expression of…
  • Abstract Number: 1512 • 2014 ACR/ARHP Annual Meeting

    Therapeutic Efficacy of a Novel Oral Small Molecule Macrophage Migration Inhibitory Factor [MIF] Inhibitor: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis

    Anderson Gaweco1,2, Samantha Palmer2, Rambon Shamilov2, Caroline Stremnitzer2, Michael Fisher2, Gregg Crichlow2, William Windsor2, Ellen M. Ginzler3 and Jefferson Tilley2, 1SUNY-Downstate Medical Center, Brooklyn, NY, 2Innovimmune Biotherapeutics, Brooklyn, NY, 3Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY

    Background/Purpose: Macrophage migration inhibitory factor [MIF] is a cytokine secreted by activated T cells and macrophages that plays an important role in RA and autoimmune…
  • Abstract Number: 511 • 2014 ACR/ARHP Annual Meeting

    First and Second Line Continuation Rates of Non Anti-TNF-α Biological DMARD for the Treatment of Rheumatoid Arthritis

    Tristan Pascart1, Rene-Marc Flipo2, Xavier Deprez3 and Eric Houvenagel4, 1Rheumatology, Saint-Philibert Hospital, Lille, France, 2Rheumatology, University Hospital Lille, Lille, France, 3Rhumatologie, Ch De Valenciennes, Valenciennes, France, 4Rheumatology, Saint-Philibert Hospital, LOMME, France

    Background/Purpose The 2013 update of the EULAR recommendations for the management of RA with synthetic and biological DMARDs set non-anti-TNF- α as first-line biological treatments.…
  • Abstract Number: 2507 • 2014 ACR/ARHP Annual Meeting

    Is There an Autoinflammatory Component in Rheumatoid Arthritis Associated with Better Response to Anakinra (Kineret®)?

    Barbara Missler-Karger1, Hans-Eckhard Langer2, Mika Leinonen3 and Björn Pilström4, 1Rheumatology consultant, Cologne, Germany, 2RHIO Research Institute, Düsseldorf, Germany, 34Pharma AB, Stockholm, Sweden, 4TA Inflammation, Swedish Orphan Biovitrum AB, Stockholm, Sweden

    Background/Purpose 458 patients with rheumatoid arthritis (RA) and inadequate response to traditional DMARDs alone and/or TNFα blocking agents were treated with the IL-1 receptor antagonist…
  • Abstract Number: 1498 • 2014 ACR/ARHP Annual Meeting

    ALX-0061, an Anti-IL-6R Nanobody® for use in Rheumatoid Arthritis, Demonstrates a Different in Vitro Profile As Compared to Tocilizumab

    Maarten Van Roy1, Ariella Van De Sompel2, Kristi De Smet2, Jasper Jacobs2, Tinneke Denayer2 and Hans Ulrichts3, 1Department of Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, 2Ablynx N.V., Zwijnaarde, Belgium, 3Pharmacology, Ablynx N.V., Zwijnaarde, Belgium

    Background/Purpose Interleukin-6 (IL-6) is a pleiotropic cytokine inducing a wide range of biological activities via its receptor, which can either be soluble (sIL-6R) or membrane-bound…
  • Abstract Number: 515 • 2014 ACR/ARHP Annual Meeting

    Dosing of Intravenous Tocilizumab in a Real-World Setting—Analyses from a US RA Registry

    Dimitrios A. Pappas1, Ani John2, Jeffrey R. Curtis3, George W. Reed4,5, Chitra Karki6, Robert Magner5, Joel M. Kremer7, Ashwini Shewade2 and Jeffrey D. Greenberg6,8, 1Columbia University, New York, NY, 2Genentech, Inc, South San Francisco, CA, 3University of Alabama at Birmingham, Birmingham, AL, 4Corrona, LLC., Southborough, MA, 5University of Massachusetts Medical School, Worcester, MA, 6Corrona, LLC, Southborough, MA, 7Albany Medical College and The Center for Rheumatology, Albany, NY, 8NYU School of Medicine, New York, NY

    Background/Purpose: In the US, the recommended starting dose of intravenous tocilizumab (TCZ) in combination with DMARDs or as monotherapy is 4 mg/kg every 4 weeks…
  • Abstract Number: 2501 • 2014 ACR/ARHP Annual Meeting

    Indirect Comparison of Tocilizumab and Tofacitinib in Patients with Rheumatoid Arthritis

    Stacey Chang1, Laura Sawyer1 and Fred Dejonckheere2, 1Symmetron Limited, London, United Kingdom, 2F. Hoffmann-La Roche, Basel, Switzerland

    Background/Purpose: Tocilizumab (TCZ) is a recombinant, humanized, monoclonal antibody directed against the cytokine interleukin-6 receptor, and tofacitinib (Tofa) is an oral, synthetic, disease-modifying antirheumatic drug…
  • Abstract Number: 1494 • 2014 ACR/ARHP Annual Meeting

    Treatment of Rheumatoid Arthritis Patients with the JAK1-Selective Inhibitor GLPG0634 Reverses an Arthritis-Specific Blood Gene Signature to Healthy State

    Mate Ongenaert1, Sonia Dupont2, Béatrice Vayssière2, Reginald Brys1, Luc Van Rompaey1, Christel Menet1 and René Galien2, 1Galapagos NV, Mechelen, Belgium, 2Galapagos SASU, Romainville, France

    Background/Purpose The 4 Janus kinases (JAK1, JAK2, JAK3 and TYK2) are cytoplasmic tyrosine kinases that mediate intracellular signaling of cytokines (e.g. certain interleukins and interferons)…
  • Abstract Number: 497 • 2014 ACR/ARHP Annual Meeting

    Efficacy and Safety Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed By Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to Traditional Disease Modifying Anti-Rheumatic Drugs

    Thomas Dörner1, Hans-Peter Tony2, Gerd Burmester1, Hendrik Schulze-Koops3, Jörg Kaufmann4, Peter Kästner5, Herbert Kellner6, Reiner Kurthen7, Sylke Wagner8, Marvin A. Peters9 and Christoph Iking-Konert10, 1Charité - Universitätsmedizin Berlin, Berlin, Germany, 2University Clinic Wuerzburg, Wuerzburg, Germany, 3University Clinic Munich, Munich, Germany, 4Rheumatology Practice, Ludwigsfelde, Germany, 5MVZ Out-patient Rheumatogy Unit Erfurt, Erfurt, Germany, 6Specialist Practice for Rheumatology and Gastroenterology, Munich, Germany, 7Rheumatology Practice, Aachen, Germany, 8Practice for Internal Medicine specialized in Rheumatology, Halle, Germany, 9Roche Pharma AG, Grenzach-Wyhlen, Germany, 10University Clinic Hamburg-Eppendorf, Hamburg, Germany

    Background/Purpose: The MIRAI study evaluated a sequential exposure to 2 defined biologics under rigorous study conditions within a homogeneous population of biological naïve patients (pts)…
  • Abstract Number: 2489 • 2014 ACR/ARHP Annual Meeting

    Analysis of Early Neutropenia, Clinical Response, and Serious Infection Events in Patients Receiving Tofacitinib for Rheumatoid Arthritis

    V. Strand1, A. Dikranian2, J. Beal3, K. Kwok3, S. Krishnaswami4, S. Wood4 and C. Nduaka4, 1Biopharmaceutical Consultant, Portola Valley, CA, 2San Diego Arthritis Medical Clinic, San Diego, CA, 3Pfizer Inc, New York, NY, 4Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Post-baseline (BL) decreases in mean peripheral neutrophil count were…
  • Abstract Number: 1463 • 2014 ACR/ARHP Annual Meeting

    Dickkopf-1 Perpetuated Synovial Fibroblast Activation and Synovial Angiogenesis in Rheumatoid Arthritis

    Li Zheng1, Fanlei Hu2, Yingni Li1, Lianjie Shi2, Xiaoxu Ma1, Xuewu Zhang3 and Zhanguo Li4, 1Peking University People's Hospital, Beijing, China, 2Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, 311 South Street, XiZhiMen , We, Peking University People's Hospital, Beijing, China, 4Rheum/Immunology, Peking University People's Hospital, Beijing, China

    Background/Purpose . Dkk-1, a master regulator of joint remodeling, is elevated and leads to bone resorption in patients with RA. This study aimed to investigate…
  • « Previous Page
  • 1
  • …
  • 176
  • 177
  • 178
  • 179
  • 180
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology